Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition

BACKGROUND: Despite intensive effort, currently no effective anti-Ras therapies have successfully reached clinical application. Previous studies suggest that the histone deacetylatse (HDAC) inhibitor romidepsin, which is currently in clinical trials for the treatment of multiple malignancies, can bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanker, Ariella B, Healy, Kevin D, Nichols, Jean, Der, Channing J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735739/
https://www.ncbi.nlm.nih.gov/pubmed/19682393
http://dx.doi.org/10.1186/1750-2187-4-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735739/
https://www.ncbi.nlm.nih.gov/pubmed/19682393
http://dx.doi.org/10.1186/1750-2187-4-5

Ejemplares similares